PALB2 and neoplasm: The genetic testing of the patient’s tumor tissue revealed the following mutations and characteristics (1): Somatic tumor mutations:An NRAS Q61K mutation was detected at a frequency of 6%;A BRAF G464E mutation was identified at a frequency of 6.9%;An ABL1 K609del mutation was identified at a frequency of 6.0%; A DNMT3A S129G mutation was identified at a frequency of 48.2%; An EPCAM A82G mutation was identified at a frequency of 48.8%; A PALB2 A38G mutation was identified at a frequency of 42.5% (2).